<div id="readability-page-1"><div><p>10 analysts have expressed a variety of opinions on Viridian Therapeutics <span>VRDN</span> over the past quarter, offering a diverse set of opinions from bullish to bearish.</p><p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p><table><thead><tr><th></th><th><strong>Bullish</strong></th><th><strong>Somewhat Bullish</strong></th><th><strong>Indifferent</strong></th><th><strong>Somewhat Bearish</strong></th><th><strong>Bearish</strong></th></tr></thead><tbody><tr><td><strong>Total Ratings</strong></td><td>7</td><td>3</td><td>0</td><td>0</td><td>0</td></tr><tr><td><strong>Last 30D</strong></td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td><strong>1M Ago</strong></td><td>2</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td><strong>2M Ago</strong></td><td>3</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td><strong>3M Ago</strong></td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td></tr></tbody></table><p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $41.2, a high estimate of $61.00, and a low estimate of $34.00. Witnessing a positive shift, the current average has risen by 3.78% from the previous average price target of $39.70.</p><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1734458424_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1734458424_0.png"/></p><h2>Investigating Analyst Ratings: An Elaborate Study</h2><p>The perception of Viridian Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p><table><thead><tr><th>Analyst</th><th>Analyst Firm</th><th>Action Taken</th><th>Rating</th><th>Current Price Target</th><th>Prior Price Target</th></tr></thead><tbody><tr><td>Gregory Renza</td><td>RBC Capital</td><td>Raises</td><td>Outperform</td><td>$47.00</td><td>$44.00</td></tr><tr><td>Douglas Tsao</td><td>HC Wainwright &amp; Co.</td><td>Maintains</td><td>Buy</td><td>$34.00</td><td>$34.00</td></tr><tr><td>Douglas Tsao</td><td>HC Wainwright &amp; Co.</td><td>Maintains</td><td>Buy</td><td>$34.00</td><td>$34.00</td></tr><tr><td>Gregory Renza</td><td>RBC Capital</td><td>Maintains</td><td>Outperform</td><td>$44.00</td><td>$44.00</td></tr><tr><td>Serge Belanger</td><td>Needham</td><td>Maintains</td><td>Buy</td><td>$38.00</td><td>$38.00</td></tr><tr><td>Douglas Tsao</td><td>HC Wainwright &amp; Co.</td><td>Raises</td><td>Buy</td><td>$34.00</td><td>$27.00</td></tr><tr><td>Serge Belanger</td><td>Needham</td><td>Maintains</td><td>Buy</td><td>$38.00</td><td>$38.00</td></tr><tr><td>Serge Belanger</td><td>Needham</td><td>Maintains</td><td>Buy</td><td>$38.00</td><td>$38.00</td></tr><tr><td>Julian Harrison</td><td>BTIG</td><td>Raises</td><td>Buy</td><td>$61.00</td><td>$56.00</td></tr><tr><td>Gregory Renza</td><td>RBC Capital</td><td>Maintains</td><td>Outperform</td><td>$44.00</td><td>$44.00</td></tr></tbody></table><h3>Key Insights:</h3><ul><li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Viridian Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li><li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Viridian Therapeutics compared to the broader market.</li><li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Viridian Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li></ul><p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Viridian Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.</p><p><strong>Stay up to date on Viridian Therapeutics analyst ratings.</strong></p><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p><h2>Discovering Viridian Therapeutics: A Closer Look</h2><p>Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.</p><h3>Breaking Down Viridian Therapeutics's Financial Performance</h3><p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p><p><strong>Revenue Growth:</strong> Viridian Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>19.44%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p><p><strong>Net Margin:</strong> Viridian Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-89173.26%,</strong> the company may face hurdles in effective cost management.</p><p><strong>Return on Equity (ROE):</strong> Viridian Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-18.08%,</strong> the company may face hurdles in achieving optimal financial returns.</p><p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-11.3%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p><p><strong>Debt Management:</strong> Viridian Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.04</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p><h2>Analyst Ratings: What Are They?</h2><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p><p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p><p><strong>Which Stocks Are Analysts Recommending Now?</strong></p><p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <strong>Click here to stay ahead of the market</strong>.</p><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p></div></div>

VRDN

<p>Ten analysts have shared diverse opinions on Viridian Therapeutics (VRDN), with ratings ranging from bullish to bearish. Recent evaluations show a positive shift in sentiment, with an average 12-month price target of $20.00, up 3.78% from the previous target. Analysts have raised or maintained ratings, reflecting their response to market dynamics. Financially, Viridian has shown a revenue growth rate of 19.44%, but faces challenges with a net margin of -89173.26% and ROE of -18.08%. The company maintains a conservative debt-to-equity ratio of 0.04, indicating lower reliance on debt financing.</p>

Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views